Inquiry Basket
Loading ......
Creative Diagnostics provides SARS-CoV-2 ADE Assay services for accurate detection and analysis of antibody-dependent enhancement (ADE) against SARS-CoV-2. We offer advanced platforms that integrate cutting-edge technologies with validated bioanalytical approaches for robust and reproducible ADE analysis with high sensitivity, reproducibility and stability. Our SARS-CoV-2 ADE Assay services are ideal for applications in vaccine research, therapeutic monitoring, and the development of targeted treatments. We provide insights into ADE potential to optimize vaccine formulations, enhance therapeutic efficacy, and fast-track development of effective interventions in both preclinical and clinical development stages.
Beckman Coulter CytoFLEX
Olympus IX83
Thermo Fisher Multiskan
Creative Diagnostics offers comprehensive SARS-CoV-2 ADE Assay services to support detailed evaluation of antibody-dependent enhancement in biological systems. Building on a wealth of experience in bioanalytical method development, cutting edge detection platforms and assay optimization, we provide the assay platforms needed to tailor ADE assays to your research questions. Our advanced systems allow for high sensitivity, specificity, and reproducible detection and characterization of ADE potential. We aid in immune response profiling, as well as vaccine and therapeutic antibody safety assessment and risk assessment of enhanced viral infectivity to help you bring vaccines and antibodies to market faster and optimize therapeutic options. We provide:
To meet the need for accurate and reliable evaluation of antibody-dependent enhancement, we provide comprehensive SARS-CoV-2 ADE Assay services. Utilizing advanced bioanalytical platforms and highly sensitive detection technologies, we achieve precise detection and characterization of ADE potential in antibody responses. The service involves optimized sample processing, validation of experimental design, and a range of different readout formats (Fc receptor-mediated entry, flow cytometry, ELISA based detection etc.) to ensure the best combination of sensitivity, specificity and biological relevance of the data. It has been used broadly in vaccine safety testing, therapeutic antibody discovery and immune monitoring applications. A strong quality control program and significant technical expertise result in high reproducibility, stability and data consistency of each project.Our core services include:
Provide detailed experimental reports with ADE risk scores, quantitative results, and visualization charts. Support research decision-making and vaccine/antibody optimization strategies.
Understand the research objectives and develop a customized ADE assessment plan.
Prepare samples and select an appropriate ADE detection method.
Detect whether antibodies may enhance SARS-CoV-2 infection.
Provide quantitative results and a detailed report.
Provide a project summary and subsequent technical support.
Quantitative ELISA analysis of SARS-CoV-2 ADE potential. OD450 values represent antibody binding to viral antigens. Antibody groups A–C are candidate therapeutic antibodies; Control represents untreated sample.
Yes, our SARS-CoV-2 ADE Assay can assess whether antibodies may facilitate viral entry into cells, helping you identify potential risks ahead of time.
Absolutely. We have optimized low-sample-volume assays to ensure reliable results.
Yes, we provide quantitative ADE risk analysis to help you optimize design and safety assessments.
Of course, we combine an Fc receptor-mediated viral entry assay, flow cytometry, and ELISA. This multi-step approach ensures high sensitivity and specificity.
Yes, we provide a detailed report and professional interpretation, and can also provide recommendations for follow-up experiments and optimization.
To use our SARS-CoV-2 ADE assay services, please contact Creative Diagnostics, your expert immunology service provider. From research-scale SARS-CoV-2 ADE assay services to scale-up, our team is ready to support your R&D innovation.
Loading ......
